We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Therapeutic Variables in Cataract Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00407017
Recruitment Status : Completed
First Posted : December 4, 2006
Last Update Posted : August 21, 2007
Sponsor:
Information provided by:

Study Description
Brief Summary:
The purpose of this study is to compare patient outcomes in following cataract surgery in patients randomized to one of two surgical kits.

Condition or disease Intervention/treatment Phase
Cataract Surgery Drug: Gatifloxacin Drug: Ketorolac LS Drug: Pred Forte Drug: Moxifloxacin Drug: Nepafenac Drug: EconoPred Plus Phase 4

Study Design

Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cataract
U.S. FDA Resources

Arms and Interventions


Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Males or females scheduled to undergo cataract surgery
  • Patients can be receiving monofocal IOLs only
  • Likely to complete all study visits and able to provide informed consent
  • Visual potential of 20/25 or better

Exclusion Criteria:

  • Known contraindications to any study medication or ingredients
  • Active ocular diseases or uncontrolled systemic disease
  • Active ocular allergies
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00407017


Locations
United States, Florida
The Center for Excellence in Eye Care
Miami, Florida, United States, 33176
Sponsors and Collaborators
Innovative Medical
Investigators
Principal Investigator: William Trattler, MD The Center For Excellence in Eye Care
More Information

ClinicalTrials.gov Identifier: NCT00407017     History of Changes
Other Study ID Numbers: 5264-T
First Posted: December 4, 2006    Key Record Dates
Last Update Posted: August 21, 2007
Last Verified: August 2007

Additional relevant MeSH terms:
Cataract
Lens Diseases
Eye Diseases
Moxifloxacin
Gatifloxacin
Methylprednisolone Hemisuccinate
Prednisolone
Ketorolac
Nepafenac
Prednisolone acetate
Methylprednisolone acetate
Methylprednisolone
Prednisolone hemisuccinate
Prednisolone phosphate
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors